Fosun Pharma subsidiary secures approval for Deferasirox drugs

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced its subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Company Limited, has received National Medical Products Administration approval for Deferasirox Tablets and Deferasirox Granules. The drugs are indicated for chronic iron overload due to blood transfusions in patients above 2 years of age, and in patients 10 years of age and older with non-transfusion-dependent thalassemia syndromes.

Deferasirox Tablets are approved in 90mg and 360mg strengths, while Deferasirox Granules are approved in a 360mg strength. Suzhou Erye Pharmaceutical Co., Ltd. is listed as the manufacturer for both. As of September 2025, Fosun Pharma had invested approximately RMB24.55 million in the research and development of these drugs.

The company projects this approval will enrich its product line. According to IQVIA CHPA data, sales of Deferasirox preparations in China (excluding Hong Kong, Macau and Taiwan) reached approximately RMB128 million in 2024. Fosun Pharma cautioned that future sales are subject to market demand, competition, and sales channels.